the common site of action at the polymerase enzyme (specifically given rib binds to the same active site as nucs) is certainly of theoretical concern. as is the replicon data
on the flip side ribavirin's antiviral activities are also felt to be mediated by non-polymerase related actions (inhibition of gtp, augmentation of helper T cell activity,etc. - all well documented effects), so this is a tough one to call and we'll have to wait and see
my bottom line is that even in the worst case scenario and there is negative interaction, nm-283 still has tremendous potential being dosed without rib to eliminate toxicity (or even better svr than soc with rib), and always have the option of sequential dosing strategies to maximize svrs
ps: very surprised by the reaction (or lack thereof) of market to yesterday's news. frankly, I don't think it has sunk in yet
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM